Faculty Opinions recommendation of Antisense oligonucleotide therapy reduces seizures and extends life span in an SCN2A gain-of-function epilepsy model.

Author(s):  
Holger Lerche ◽  
Ulrike Hedrich
2021 ◽  
Vol 131 (23) ◽  
Author(s):  
Melody Li ◽  
Nikola Jancovski ◽  
Paymaan Jafar-Nejad ◽  
Lisseth E. Burbano ◽  
Ben Rollo ◽  
...  

1996 ◽  
Vol 334 (5) ◽  
pp. 316-318 ◽  
Author(s):  
Frederick K. Askari ◽  
W. Michael McDonnell

2012 ◽  
Vol 1 ◽  
pp. e58 ◽  
Author(s):  
Francesca Amati ◽  
Laura Diano ◽  
Lucia Vecchione ◽  
Giuseppe Danilo Norata ◽  
Yoshikazu Koyama ◽  
...  

Author(s):  
Kavya Pandiri ◽  
Mohammed Abdul Samad ◽  
Nadeem Abbas Gulamus ◽  
Hajera Khanam

Antisense technology has emerged as a fast and conceivably high-throughput method for repressing genes due to advancement in knowledge about DNA and RNA physiology. The limitations of antisense oligonucleotide therapy in delivery strategies have been overcome in recent years. Antisense oligonucleotide treatment was effectively applied towards targeting a wide range of therapeutic areas. With ongoing approvals of antisense oligonucleotides, there is an expanding enthusiasm for increasing the utilization of these compounds for curing various infections. This short survey gives a far-reaching comprehension of applications of antisense technology, how they can be utilized therapeutically, and current endeavors to grow new antisense oligonucleotide treatments that will add a forthcoming therapeutic approach for the treatment of various diseases.


Sign in / Sign up

Export Citation Format

Share Document